Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MACK

Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis

Merrimack Pharmaceuticals logo

About Merrimack Pharmaceuticals Stock (NASDAQ:MACK)

Advanced Chart

Key Stats

Today's Range
$15.13
$15.13
50-Day Range
$14.65
$15.13
52-Week Range
$11.53
$15.89
Volume
N/A
Average Volume
396,929 shs
Market Capitalization
$223.77 million
P/E Ratio
1.09
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Stock News Headlines

F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLaren Engineering, a NASDAQ-listed marine tech company unveiled a groundbreaking new electric powertrain set to transform the industry.
See More Headlines

MACK Stock Analysis - Frequently Asked Questions

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) posted its quarterly earnings data on Friday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.14.

Shares of Merrimack Pharmaceuticals reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Merrimack Pharmaceuticals investors own include Rite Aid (RAD), Agenus (AGEN), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY) and Meta Platforms (META).

Company Calendar

Last Earnings
5/10/2019
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MACK
Previous Symbol
NASDAQ:MACK
Employees
426
Year Founded
2000

Profitability

Trailing P/E Ratio
1.09
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$1.18 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.31 per share
Price / Book
11.55

Miscellaneous

Free Float
10,267,000
Market Cap
$223.77 million
Optionable
Optionable
Beta
1.45

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:MACK) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners